Navigation Links
Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry

In the agreement between the two Toronto-area companies, Microbix will maintain sales and marketing functions while Therapure will manage manufacturing, distribution and product development

TORONTO, Jan. 12 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (MBX:TSX), a biotechnology company focused on virology and biological technologies, and Therapure Biopharma Inc., an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins, announced today the signing of a partnership agreement to manufacture and market water-based products to the pharmaceutical, biotechnology and other industries.

The partnership will significantly expand the portfolio of products Microbix will offer its customers and increase capacity by leveraging Therapure's state-of-the-art, commercial scale manufacturing facility. Under terms of the agreement, Microbix will maintain the sales and marketing functions for the water-based program, while Therapure will manage manufacturing and product development operations. The products will remain under the Microbix brand. Further financial details of the transaction were not made public.

Microbix, whose water-based product sales have nearly doubled each year since 2006, will benefit from the agreement due to Therapure's large manufacturing capacity, its R&D expertise as well as its testing, filling, packaging and shipping services. Therapure will gain by tapping into Microbix' established market position as a leading water-based products supplier to the North American pharmaceutical industry.

Microbix CEO William J. Gastle said "Therapure's capabilities will enable Microbix to expand our product line and market share of the growing water-based business in North America. Our partnership will enable us to provide a complete portfolio of water-based products which will drive sales higher while increasing customer satisfaction."

"Water-based products are an important part of Microbix' core business, which has been growing by more than 20% annually for the past six years," Mr. Gastle added.

Thomas Wellner, President and CEO of Therapure said "Therapure Biopharma is excited to partner with another Canadian-based biotechnology company. This opportunity enables Therapure to leverage our large water and buffer manufacturing capacity and our Health Canada licensed aseptic filling capabilities."

The immediate result of the Microbix-Therapure agreement will be the launch of Microbix 22(TM), a new 22% alcohol and water-for-injection (WFI) pre-mixed used for chromatography column storage. Mixing concentrated alcohol with water can be dangerous and many customers would rather purchase the product premixed and avoid the risks. Additionally, the partnership will be able to manufacture custom buffers and media to recipes provided by customers.

About Microbix

Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto.

About Therapure Biopharma

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO), Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its' clients. Therapure's Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.

This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to develop and commercialize new products on a timely basis, non-adoption of products by new customers, resistance to business model for commercialization and implementation; risks associated with commercializing new products; and risks associated with outsourcing production including control over costs, quality, quantity and timeliness of delivery of products. These forward-looking statements represent the Companies' judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.

SOURCE Microbix Biosystems Inc.

SOURCE Microbix Biosystems Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Microbix Pipeline Set To Reach Milestones In 2010
2. Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region
3. Microbix Biosystems Re-files Annual Results With OSC
4. Microbix Biosystems Provides a Corporate Update
5. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility
6. Microbix Sales Grow 22% For Nine Months
7. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
8. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
9. Microbix Announces A New Technology Platform For The SST Project
10. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
11. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th ... Paris from 17 th until 19 th ... leader, has invented the first combined scanner in the world ... scanning surface. Until now two different scanners were required: one ... both on the same surface. This innovation is an ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
(Date:11/11/2015)... MINNETONKA, Minn. , Nov. 11, 2015   MedNet ... the entire spectrum of clinical research, is pleased to announce ... Partnerships in Clinical Trials (PCT) event, to be held ... will be able to view live demonstrations of ... platform, and learn how iMedNet has been able ...
Breaking Biology News(10 mins):